Lumos Pharma's Abstracts to be Presented at ENDO 2024

AUSTIN, Texas, May 20, 2024 -- Lumos Pharma, Inc. (NASDAQ:LUMO), a company specializing in therapeutics for rare diseases, announced that fresh analyses from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials will be showcased at the 2024 Annual Meeting of the Endocrine Society (ENDO) in Boston, MA, from June 1-4, 2024.

The company will present its findings through two posters. The first session, Poster Session P069, is scheduled for Monday, June 3, from 12:00-1:30 PM ET. Poster MON-111, titled "Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Hormone Deficiency (PGHD): Key Discoveries from Phase 2 of OraGrowtH212 Trial," will be presented by Dr. Fernando Cassorla, Chief of Pediatric Endocrinology at the University of Chile, along with other researchers.

The second presentation, part of the Late-Breaking Poster Session P108, will also be held on Monday, June 3, from 12:00-1:30 PM ET. Poster MON-704, titled "Growth Response to Oral Growth Hormone Secretagogue LUM-201 in Children with Moderate GH Deficiency (GHD) is dependent on the Pattern of Pulsatile GH Secretion Stimulated by LUM-201," will be presented by Dr. Adam Stevens, a lecturer at the University of Manchester, and his team.

Lumos Pharma, Inc. is a biopharmaceutical company at the clinical stage, concentrating on developing and commercializing treatments for rare diseases. The company is guided by a management team with extensive experience in the field of rare disease drug development. Its lead therapeutic candidate, LUM-201, is a novel oral growth hormone secretagogue. This innovative treatment aims to revolutionize the approximate $4.7 billion global growth hormone market by shifting from injectable to oral therapy.

LUM-201 is currently undergoing evaluation in multiple Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD). It has also received Orphan Drug Designation in both the United States and the European Union. This designation typically provides various benefits, including market exclusivity, tax credits, and assistance with clinical trial design, which can help expedite the drug’s development and approval process.

By bringing forward LUM-201, Lumos Pharma aspires to offer a less invasive and more convenient treatment option for patients suffering from conditions related to growth hormone deficiency. The ability to administer a growth hormone secretagogue orally would represent a significant shift from the conventional injectable treatments, potentially improving patient compliance and quality of life.

This year's ENDO meeting provides a prominent platform for Lumos Pharma to share their promising findings with the scientific community, potentially paving the way for further advancements in the treatment of moderate Pediatric Growth Hormone Deficiency.

As Lumos Pharma continues to advance its clinical programs, the company remains committed to addressing the unmet needs in the realm of rare diseases, with a focused mission to improve the lives of patients through innovative therapeutic solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!